ギラン・バレー症候群の市場：タイプ、治療、エンドユーザー別-2025-2030年の世界予測

ギラン・バレー症候群市場は、2023年に6億3,443万米ドルと評価され、2024年には6億6,539万米ドルに達すると予測され、CAGR 2.10％で成長し、2030年には7億3,424万米ドルに達すると予測されています。

ギラン・バレー症候群（GBS）は、末梢神経系に影響を及ぼす急性の免疫介在性疾患で、急速に進行する脱力感や潜在的な麻痺を引き起こします。360iResearchの市場調査アナリストとして、GBS関連の医療介入と治療の範囲、必要性、用途を理解することは極めて重要です。GBSは主に、迅速な医療診断、免疫療法、リハビリテーションサービスを必要とするため、神経科クリニック、病院、リハビリテーションセンターでの需要が高まっています。世界の罹患率の上昇に伴い、認知度の向上と診断技術の強化により、GBS市場は成長の態勢を整えています。主な成長要因としては、支持療法の進歩に加え、免疫グロブリン静脈注射やプラズマフェレーシスなどの治療ソリューションの進歩が挙げられます。また、製薬企業による新規治療に対するヘルスケア投資と研究資金の増加も市場を前進させる。さらに、自己免疫疾患に罹患しやすい高齢化社会が需要を牽引しています。しかし、治療に関する高額な費用や、GBSの正確な診断の複雑さ、さらに他の神経疾患との症状の類似性による誤診のおそれなど、市場は限界に直面しています。規制上の課題や新規治療薬の厳しい承認プロセスがハードルとなり、市場拡大をさらに複雑にしています。このような課題にもかかわらず、現在の治療レジメン以上の進歩を目指した革新的な治療薬の開発には機会があふれています。個別化医療、再生療法、ゲノム・ソリューションといった新たな領域は、差別化と成長のためのエキサイティングな展望を提供します。さらに、正確な早期診断のためにAIと機械学習を活用することは、患者の転帰に革命をもたらし、長期的なビジネスチャンスを提供する可能性があります。最後に、臨床試験や研究を実施するための学術機関とヘルスケア企業の連携は、イノベーションを促進する可能性があります。したがって、進化するGBS市場で牙城を築くことを目指す企業にとって、強固な研究開発、戦略的パートナーシップ、効率的なヘルスケア提供システムの重視は極めて重要であろう。

市場力学：急速に進化するギラン・バレー症候群市場の主要市場インサイトを公開

ギラン・バレー症候群市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のギラン・バレー症候群の普及拡大
  • ギラン・バレー症候群治療における免疫グロブリン静脈注射の採用拡大
  • 消費者のヘルスケアに対する意識と支出の増加
• 市場抑制要因
  • 治療費および薬剤費の高騰
• 市場機会
  • ギラン・バレー症候群の管理における進歩
  • 希少疾患に対する政府の好意的な償還政策
• 市場の課題
  • 病気の診断と治療に対する意識の低さ

ポーターのファイブフォース：ギラン・バレー症候群市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ギラン・バレー症候群市場における外部からの影響の把握

外部マクロ環境要因は、ギラン・バレー症候群市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ギラン・バレー症候群市場における競合情勢の把握

ギラン・バレー症候群市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスギラン・バレー症候群市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ギラン・バレー症候群市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ギラン・バレー症候群市場における成功への道筋を描く

ギラン・バレー症候群市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でギラン・バレー症候群の普及が増加
    • 静脈内免疫グロブリンの採用が拡大ギラン・バレー症候群の治療に
    • 消費者のヘルスケア意識と支出の増加
  • 抑制要因
    • 治療と薬剤費の高騰
  • 機会
    • ギラン・バレー症候群の管理の進歩
    • 希少疾患に対する政府の有利な医療費償還政策
  • 課題
    • 病気の診断と治療に対する意識が低い
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ギラン・バレー症候群の市場：タイプ別

• 急性炎症性脱髄性多発神経炎
• 急性運動・感覚軸索ニューロパチー
• 急性運動軸索性ニューロパチー
• ミラー・フィッシャー症候群

第7章 ギラン・バレー症候群の市場治療別

• ハイドロセラピー
• 薬物治療
• 理学療法
• 血漿交換

第8章 ギラン・バレー症候群の市場：エンドユーザー別

• 診断センター
• 病院

第9章 南北アメリカのギラン・バレー症候群の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のギラン・バレー症候群の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのギラン・バレー症候群の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Akari Therapeutics Plc
• Annexon Inc.
• Cellenkos Inc.
• CSL Limited
• CuraVac Europe S.A.
• Electrical Geodesics Inc.
• Grifols S.A.
• Hansa Biopharma
• Kedrion Biopharma Inc.
• Octapharma AG
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GUILLAIN-BARRE SYNDROME MARKET DYNAMICS
• TABLE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR & SENSORY AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MILLER FISHER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

The Guillain-Barre Syndrome Market was valued at USD 634.43 million in 2023, expected to reach USD 665.39 million in 2024, and is projected to grow at a CAGR of 2.10%, to USD 734.24 million by 2030.

Guillain-Barre Syndrome (GBS) is an acute, immune-mediated disorder affecting the peripheral nervous system, leading to rapidly progressing weakness and potential paralysis. As a market research analyst at 360iResearch, it is vital to understand the scope, necessity, and applications of GBS-related medical interventions and treatments. GBS primarily requires rapid medical diagnosis, immunotherapy, and rehabilitation services, leading to growing demand in neurology clinics, hospitals, and rehabilitation centers. With an increasing incidence rate globally, attributed to rising awareness and enhanced diagnostic techniques, the GBS market is poised for growth. Key growth factors include advancements in therapeutic solutions, such as intravenous immunoglobulins and plasmapheresis, alongside advancements in supportive care. Increasing healthcare investment and research funding for novel therapies by pharmaceutical companies also propel the market forward, while the aging population, more prone to autoimmune disorders, drives demand. However, the market faces limitations, including high costs associated with treatment and the complexity of accurately diagnosing GBS, compounded by a threat of misdiagnosis due to symptom similarity with other neurological disorders. Regulatory challenges and stringent approval processes for new therapies present hurdles, further complicating market expansion. Despite these challenges, opportunities abound in the development of innovative therapeutics aimed at advancing beyond current treatment regimens. Emerging areas such as personalized medicine, regenerative therapy, and genomic solutions offer exciting prospects for differentiation and growth. Additionally, leveraging AI and machine learning for accurate early diagnosis could revolutionize patient outcomes, offering long-term business opportunities. Lastly, collaboration between academic institutions and healthcare companies to conduct clinical trials and research can drive innovation. Therefore, an emphasis on robust R&D, strategic partnerships, and efficient healthcare delivery systems will be crucial for companies aiming to establish a stronghold in the evolving GBS market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Guillain-Barre Syndrome Market

The Guillain-Barre Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of Guillain-Barre syndrome worldwide
  • Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
  • Rising consumer healthcare awareness and expenditures
• Market Restraints
  • High costs of treatment and drugs
• Market Opportunities
  • Advances in management of Guillain-Barre syndrome
  • Favorable governmental reimbursement policies for rare diseases
• Market Challenges
  • Less awareness towards disease diagnosis and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Guillain-Barre Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Guillain-Barre Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Guillain-Barre Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Guillain-Barre Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Guillain-Barre Syndrome Market

A detailed market share analysis in the Guillain-Barre Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Guillain-Barre Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Guillain-Barre Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Guillain-Barre Syndrome Market

A strategic analysis of the Guillain-Barre Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Guillain-Barre Syndrome Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics Plc, Annexon Inc., Cellenkos Inc., CSL Limited, CuraVac Europe S.A., Electrical Geodesics Inc., Grifols S.A., Hansa Biopharma, Kedrion Biopharma Inc., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Guillain-Barre Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy, and Miller Fisher Syndrome.
• Based on Treatment, market is studied across Hydrotherapy, Medication, Physical Therapy, and Plasmapheresis.
• Based on End-User, market is studied across Diagnostic Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of Guillain-Barre syndrome worldwide
    • 5.1.1.2. Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
    • 5.1.1.3. Rising consumer healthcare awareness and expenditures
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of treatment and drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in management of Guillain-Barre syndrome
    • 5.1.3.2. Favorable governmental reimbursement policies for rare diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Less awareness towards disease diagnosis and treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Guillain-Barre Syndrome Market, by Type

• 6.1. Introduction
• 6.2. Acute Inflammatory Demyelinating Polyneuropathy
• 6.3. Acute Motor & Sensory Axonal Neuropathy
• 6.4. Acute Motor Axonal Neuropathy
• 6.5. Miller Fisher Syndrome

7. Guillain-Barre Syndrome Market, by Treatment

• 7.1. Introduction
• 7.2. Hydrotherapy
• 7.3. Medication
• 7.4. Physical Therapy
• 7.5. Plasmapheresis

8. Guillain-Barre Syndrome Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Centers
• 8.3. Hospitals

9. Americas Guillain-Barre Syndrome Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Guillain-Barre Syndrome Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Guillain-Barre Syndrome Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akari Therapeutics Plc
• 2. Annexon Inc.
• 3. Cellenkos Inc.
• 4. CSL Limited
• 5. CuraVac Europe S.A.
• 6. Electrical Geodesics Inc.
• 7. Grifols S.A.
• 8. Hansa Biopharma
• 9. Kedrion Biopharma Inc.
• 10. Octapharma AG
• 11. Takeda Pharmaceutical Company Limited